Teniposide
C32H32O13S
656.65
Furo[3′,4′:6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[4,6-O-(2-thienylmethylene)-β-d-glucopyranosyloxy]-, [5R-[5α,5aβ,8aα,9β(R*)]]-;
4′-Demethylepipodophyllotoxin 9-[4,6-O-(R)-2-thenylidene-β-d-glucopyranoside];
(5S,5aR,8aR,9R)-9-(4-Hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3′,4′:6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-(thiophen-2-ylmethylidene)-β-d-glucopyranoside [29767-20-2]
Furo[3′,4′:6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[4,6-O-(2-thienylmethylene)-β-d-glucopyranosyloxy]-, [5R-[5α,5aβ,8aα,9β(R*)]]-;
4′-Demethylepipodophyllotoxin 9-[4,6-O-(R)-2-thenylidene-β-d-glucopyranoside];
(5S,5aR,8aR,9R)-9-(4-Hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3′,4′:6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-(thiophen-2-ylmethylidene)-β-d-glucopyranoside [29767-20-2]
BRIEFING
Teniposide. This proposal is based on the version of the monograph official as of May 1, 2020. It is proposed to omit this monograph for the following reasons:
-
No drug products formulated with Teniposide are currently marketed in the United States.
-
Drug products containing Teniposide are currently not used in veterinary medicine in the United States.
(SM3: N. Myers)
Correspondence Number—C326113